Axogen Inc vs Lowe`s Companies Inc — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while Lowe`s Companies Inc trades at $216.06 (market cap $124.06B). The key difference: Lowe`s Companies Inc is far larger — about 47.5× Axogen Inc's market cap, and Lowe`s Companies Inc pays a 2.26% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | LOW | |
|---|---|---|
Market Cap | $2.61B | $124.06B |
Sector | Technology | Consumer Cyclical |
52-Week High | $48.48 | $287.39 |
52-Week Low | $14.16 | $201.92 |
Enterprise Value | $2.52B | $165.81B |
Dividend Yield | — | 2.26% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.
Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.
Lowe's Companies (LOW) trades at $217.20, down 0.75% on the day, as the home improvement retailer prepares for its Q2 2026 earnings release on August 19. The stock shows strong fundamental performance with three consecutive quarterly EPS beats and positive cash flow generation of $840 million in 2025. Technical indicators suggest a bullish trend with moving averages supporting upward momentum, though RSI levels indicate potential overbought conditions near-term. Analyst consensus remains strongly positive with a $257.06 price target representing 18% upside potential.
Lowe's presents a compelling investment case with solid profitability metrics and consistent earnings outperformance, though investors face risks from declining revenue trends and elevated debt levels. The company's strategic investments in community programs and skilled trades training demonstrate long-term commitment, while near-term focus remains on Pro business growth and same-store sales improvement. Current valuation appears reasonable with P/E of 18.7 and P/S of 1.4, suggesting potential for appreciation if Q2 results meet or exceed expectations.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →